SAN LUIS OBISPO, Calif., May 19, 2004 (PRIMEZONE) -- H. Bana Ltd., a wholly-owned subsidiary of 12 to 20 Plus, Inc. (OTCBB:TTTP), reports the results of its Hinoki Bana formulation product performance and clinical testing were significant as 92% of the participants were satisfied with the results of the treatment to fight hair loss.
Hinoki Bana is a complete system for hair health, creating the best environment for scalp restoration, perceptible reduction in hair loss and revitalized hair. Companion products essential to the Hinoki Bana thinning hair treatment system include a technically sophisticated shampoo and conditioner and a bionutrient dietary supplement providing bioactive factors to create stronger, healthier, thicker hair.
Gar Laboratories, Inc. a 20-year Southern California FDA-registered commercial contract manufacturer with a 72,000 square foot facility, full-service R&D lab and three on-staff chemists has been awarded the contract to produce the line to H. Bana Ltd. specifications. H. Bana Ltd. will sell the product through its international distribution channels.
About 12 to 20 Plus, Incorporated
12 to 20 Plus, Incorporated is a research-based nutraceutical company and a pioneer in the emerging field of specialized nutritional formulas and nutraceuticals. One of the company's flagship products, the Zit Stick(r), is part of a "spa style" acne therapy system(tm). The market for acne remedies is expected to reach $370 million in 2004. 12 to 20 Plus, Inc. also markets highly effective condition-specific dietary supplements containing the most sophisticated combination of extensively researched nutritional elements available. The products are manufactured by FDA-approved labs and do not contain herbs. Instead, the company utilizes potent pharmaceutical grade "amino acids", important protein constituents that serve as neurotransmitter precursors, membrane stabilizers and enzyme precursors. Some of (NRG) products include Anaplex (tm), the antidepressant drug alternative; VisionKare(tm), an advanced supplement for macular degeneration; ChemoKare(tm), a unique combination of extracts designed to treat the side effects of chemotherapy; QuitSystem(r), a neuronutrient supplementation for recovery from alcohol, drugs and smoking; Hinoki Bana(tm), a treatment for men and women with hair loss problems. Retail sales in the explosive dietary supplement market are expected to hit almost $40 billion by year 2007; higher numbers than earlier projected by Frost & Sullivan reports.
This release contains forward-looking statements and projections. Such statements and projections are made under the safe harbor provisions of applicable laws and regulations. Any reader should be advised that factors such as development of new capital funding, competition, lack of expert personnel and other factors may materially affect in an adverse manner actual results of operations. Further, any reader of this release should seek competent advice from a registered broker or financial planner prior to investing in shares of the issuer.